Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Instagram Outage Disrupts Thousands of U.S. Users 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
IRVINE, Calif., Aug. 04, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against IntelliPharmaCeutics International Inc. (“IntelliPharmaCeutics” or the “Company”) (Nasdaq:IPCI). Investors who purchased or otherwise acquired shares between January 14, 2016 and July 26, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the September 29, 2017 lead plaintiff motion deadline.
If you purchased IntelliPharmaCeutics shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone: (949) 419-3834, or via e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, IntelliPharmaCeutics made false and/or misleading statements and/or failed to disclose: that the Company failed to conduct a human abuse liability study to support its Rexista New Drug Application (“NDA”); that IntelliPharmaCeutics did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways; that the Company was not submitting sufficient data to support approval of the NDA; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
On July 24, 2017, scientists from the Food & Drug Administration (“FDA”) expressed concerns that the Company failed to provide sufficient data about the abuse potential of its opioid painkilling drug, Rexista. On July 26, 2017, IntelliPharmaCeutics announced that two advisory committees of the FDA voted 22 to 1 to oppose the Company’s New Drug Application for Rexista, citing insufficient data regarding the abuse-deterrent properties of the drug as a motivating concern. When this news was announced, the Company’s share price dropped materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
